Close Menu

In Nature this week, researchers at Rockefeller University in New York say intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. The researchers generated humanized DC-SIGN mice to demonstrate that the anti-inflammatory activity of immunoglobulin can be recreated by the transfer of bone-marrow-derived sFc-treated hDC-SIGN+ macrophages or dendritic cells into naive recipients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.